Investor profile
Bristol Myers Squibb has backed 7 European tech companies across 7 funding rounds between 2018 and 2025, joining rounds totalling €456M. Most active in Healthtech. Data as of 7 Aug 2026.
Also recorded as: Bristol Myers-Squibb
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 1 | €114M |
| Galecto Biotech | Denmark | 1 | €79M |
| Owkin | France | 1 | €74M |
| Cardior Pharmaceuticals | Germany | 1 | €64M |
| TreeFrog Therapeutics | France |
| Company | Stage | Amount | Date |
|---|---|---|---|
| GlycoEra | Series B | €114M | 2025-05 |
| Galecto Biotech | Series C | €79M | 2018-10 |
| Owkin | Series B | €74M | 2022-06 |
| Cardior Pharmaceuticals |
| 1 |
| €64M |
| Transition Bio | UK | 1 | €47M |
| IMIDomics | Spain | 1 | €14M |
| Series B |
| €64M |
| 2021-08 |
| TreeFrog Therapeutics | Series B | €64M | 2021-09 |
| Transition Bio | Series A | €47M | 2022-06 |
| IMIDomics | Other | €14M | 2021-07 |
